MedTrace Logo

A Study LY2228820 for Recurrent Ovarian Cancer

NCT01663857 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2019-09-11

Study results available
· View outcomes & findings →

Summary

A study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy.

Conditions

Interventions

DRUG

LY2228820

Administered Orally

DRUG

Carboplatin

Administered IV

DRUG

Placebo

Administered Orally

DRUG

Gemcitabine

Administered IV

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9am-5pm Eastern time *UTC/GMT-5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2017-05-25
Completion
2018-05-11

Countries

  • United States
  • Australia
  • Belgium
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01663857 on ClinicalTrials.gov